Pacira BioSciences, Inc. (PCRX) 10-Year Financial Performance & Capital Metrics

PCRX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

AboutPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Show more

Revenue $701M +3.9%
EBITDA $5M -96.7%
Net Income -$100M -337.3%
EPS (Diluted) -2.15 -341.6%
Gross Margin 75.69% +4.2%
EBITDA Margin 0.77% -96.8%
Operating Margin -10.47% -180.6%
Net Margin -14.2% -328.5%
ROE -12.08% -336.8%
ROIC -4.5% -193.7%
Debt/Equity 0.82 +21.9%
Interest Coverage -4.43 -187.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 25.5% free cash flow margin
✓Strong 5Y sales CAGR of 10.7%
✓Share count reduced 11.0% through buybacks
✓Trading at only 1.2x book value

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.49%

5Y10.73%

3Y8.98%

TTM3.14%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM123.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM121.93%

ROCE

10Y Avg0.89%

5Y Avg3.32%

3Y Avg1.44%

Latest-5.39%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	249M	276.37M	286.63M	337.28M	421.03M	429.65M	541.53M	666.82M	674.98M	700.97M
Revenue Growth %	0.26%	0.11%	0.04%	0.18%	0.25%	0.02%	0.26%	0.23%	0.01%	0.04%
Cost of Goods Sold+	71.84M	110.1M	87.92M	86.84M	106.71M	117.33M	140.25M	199.29M	184.67M	170.43M
COGS % of Revenue	0.29%	0.4%	0.31%	0.26%	0.25%	0.27%	0.26%	0.3%	0.27%	0.24%
Gross Profit+	177.16M	166.27M	198.72M	250.43M	314.31M	312.32M	401.28M	467.53M	490.31M	530.54M
Gross Margin %	0.71%	0.6%	0.69%	0.74%	0.75%	0.73%	0.74%	0.7%	0.73%	0.76%
Gross Profit Growth %	0.47%	-0.06%	0.2%	0.26%	0.26%	-0.01%	0.28%	0.17%	0.05%	0.08%
Operating Expenses+	167.71M	198.29M	218.78M	232.95M	303.83M	265.97M	311.35M	407.5M	402.63M	603.91M
OpEx % of Revenue	0.67%	0.72%	0.76%	0.69%	0.72%	0.62%	0.57%	0.61%	0.6%	0.86%
Selling, General & Admin	139.04M	152.61M	161.49M	177.26M	200.78M	193.52M	199.34M	254.52M	269.44M	294.1M
SG&A % of Revenue	0.56%	0.55%	0.56%	0.53%	0.48%	0.45%	0.37%	0.38%	0.4%	0.42%
Research & Development	28.66M	45.68M	57.29M	55.69M	72.12M	59.42M	55.55M	84.8M	76.26M	81.58M
R&D % of Revenue	0.12%	0.17%	0.2%	0.17%	0.17%	0.14%	0.1%	0.13%	0.11%	0.12%
Other Operating Expenses	-165K	-82K	167K	-888K	30.93M	13.03M	56.46M	68.19M	56.94M	228.23M
Operating Income+	9.46M	-32.02M	-24.94M	15.91M	10.48M	46.35M	89.92M	60.02M	87.67M	-73.37M
Operating Margin %	0.04%	-0.12%	-0.09%	0.05%	0.02%	0.11%	0.17%	0.09%	0.13%	-0.1%
Operating Income Growth %	2.83%	-4.39%	0.22%	1.64%	-0.34%	3.42%	0.94%	-0.33%	0.46%	-1.84%
EBITDA+	20.93M	-19.11M	-11.1M	29.08M	30.06M	66.26M	118.47M	151.53M	163.25M	5.41M
EBITDA Margin %	0.08%	-0.07%	-0.04%	0.09%	0.07%	0.15%	0.22%	0.23%	0.24%	0.01%
EBITDA Growth %	3.3%	-1.91%	0.42%	3.62%	0.03%	1.2%	0.79%	0.28%	0.08%	-0.97%
D&A (Non-Cash Add-back)	11.47M	12.92M	13.83M	13.16M	19.58M	19.91M	28.55M	91.5M	75.57M	78.78M
EBIT	9.46M	-31.39M	-25.8M	19.89M	11.17M	43.6M	85.4M	48.88M	79.01M	-49.67M
Net Interest Income+	-7.05M	-5.74M	-13.97M	-15.45M	-16.25M	-21.04M	-28.1M	-31.03M	-5.87M	3.12M
Interest Income	678K	1.32M	4.08M	6.5M	7.38M	4.63M	896K	4.54M	11.44M	19.69M
Interest Expense	7.72M	7.06M	18.05M	21.95M	23.63M	25.67M	29M	35.58M	17.31M	16.57M
Other Income/Expense	-7.33M	-5.82M	-17.53M	-16.34M	-21.23M	-26.26M	-33.52M	-46.72M	-25.97M	10.27M
Pretax Income+	2.12M	-37.84M	-42.47M	-425K	-10.75M	20.09M	56.4M	13.3M	61.7M	-63.11M
Pretax Margin %	0.01%	-0.14%	-0.15%	-0%	-0.03%	0.05%	0.1%	0.02%	0.09%	-0.09%
Income Tax+	264K	105K	140K	46K	268K	-125.43M	14.42M	-2.61M	19.75M	36.45M
Effective Tax Rate %	0.88%	1%	1%	1.11%	1.02%	7.24%	0.74%	1.2%	0.68%	1.58%
Net Income+	1.86M	-37.95M	-42.61M	-471K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M
Net Margin %	0.01%	-0.14%	-0.15%	-0%	-0.03%	0.34%	0.08%	0.02%	0.06%	-0.14%
Net Income Growth %	1.14%	-21.45%	-0.12%	0.99%	-22.39%	14.21%	-0.71%	-0.62%	1.64%	-3.37%
Net Income (Continuing)	1.86M	-37.95M	-42.61M	-471K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.04	-1.02	-1.07	-0.01	-0.27	3.33	0.92	0.34	0.89	-2.15
EPS Growth %	1.1%	-26.5%	-0.05%	0.99%	-22.48%	13.33%	-0.72%	-0.63%	1.62%	-3.42%
EPS (Basic)	0.05	-1.02	-1.07	-0.01	-0.27	3.41	0.95	0.35	0.91	-2.15
Diluted Shares Outstanding	41.3M	37.24M	39.81M	40.91M	41.51M	43.68M	45.63M	46.54M	51.98M	46.24M
Basic Shares Outstanding	36.54M	37.2M	39.81M	40.91M	41.51M	42.67M	44.26M	45.52M	46.22M	46.24M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	252.58M	243.09M	391.11M	477.97M	408.56M	651.62M	866.05M	498.33M	509.99M	745.13M
Cash & Short-Term Investments	158.97M	172.6M	311.35M	383.45M	291.95M	521.66M	656.41M	288.65M	278.58M	484.62M
Cash Only	158.97M	35.94M	54.13M	132.53M	78.23M	99.96M	585.58M	104.14M	153.3M	276.77M
Short-Term Investments	0	136.65M	257.22M	250.93M	213.72M	421.7M	70.83M	184.51M	125.28M	207.84M
Accounts Receivable	25.86M	29.94M	31.66M	38M	47.53M	53.05M	96.32M	98.4M	105.56M	113.3M
Days Sales Outstanding	37.9	39.54	40.31	41.12	41.21	45.06	64.92	53.86	57.08	59
Inventory	61.65M	31.28M	41.41M	48.57M	58.3M	64.65M	98.55M	96.06M	104.35M	125.28M
Days Inventory Outstanding	313.21	103.69	171.93	204.13	199.4	201.12	256.47	175.94	206.25	268.31
Other Current Assets	6.12M	9.28M	6.69M	7.95M	0	0	0	15.22M	21.5M	21.93M
Total Non-Current Assets+	137.04M	148.38M	237.26M	211.38M	422.51M	622.89M	1.21B	1.18B	1.06B	808.39M
Property, Plant & Equipment	90.32M	101.02M	107.05M	108.67M	142.81M	211.18M	264.81M	254.39M	234.95M	216.39M
Fixed Asset Turnover	2.76x	2.74x	2.68x	3.10x	2.95x	2.03x	2.04x	2.62x	2.87x	3.24x
Goodwill	30.88M	46.74M	55.2M	62.04M	99.55M	99.55M	145.18M	163.24M	163.24M	0
Intangible Assets	81K	0	0	0	104.39M	96.52M	623.97M	540.55M	483.26M	425.97M
Long-Term Investments	13.46M	0	74.19M	40.02M	64.8M	95.46M	0	37.21M	2.41M	29.45M
Other Non-Current Assets	2.29M	624K	825K	657K	10.97M	14.02M	21.99M	27.17M	36.05M	6.2M
Total Assets+	389.62M	391.47M	628.37M	689.35M	831.07M	1.27B	2.08B	1.68B	1.57B	1.55B
Asset Turnover	0.64x	0.71x	0.46x	0.49x	0.51x	0.34x	0.26x	0.40x	0.43x	0.45x
Asset Growth %	0.19%	0%	0.61%	0.1%	0.21%	0.53%	0.63%	-0.19%	-0.06%	-0.01%
Total Current Liabilities+	151.68M	44.84M	56.22M	60.66M	107.67M	253.33M	521.12M	147.77M	97.38M	309.92M
Accounts Payable	8.74M	7.51M	14.66M	14.37M	12.8M	10.43M	10.54M	15.22M	15.7M	19.13M
Days Payables Outstanding	44.4	24.9	60.86	60.39	43.78	32.45	27.44	27.87	31.03	40.98
Short-Term Debt	104.04M	0	324K	338K	0	149.65M	374.7M	33.65M	8.64M	201.78M
Deferred Revenue (Current)	1000K	595K	102K	0	0	0	0	0	0	0
Other Current Liabilities	23.43M	25.44M	28.76M	1.62M	40.44M	36.94M	45.49M	26.2M	42.56M	28.81M
Current Ratio	1.67x	5.42x	6.96x	7.88x	3.79x	2.57x	1.66x	3.37x	5.24x	2.40x
Quick Ratio	1.26x	4.72x	6.22x	7.08x	3.25x	2.32x	1.47x	2.72x	4.17x	2.00x
Cash Conversion Cycle	306.71	118.33	151.39	184.87	196.82	213.74	293.95	201.92	232.31	286.33
Total Non-Current Liabilities+	19.55M	127.65M	292.67M	307.47M	368.45M	401.5M	823.83M	758.42M	606.87M	465.25M
Long-Term Debt	0	108.74M	276.17M	290.59M	306.05M	313.03M	674.53M	655.82M	513.8M	383.55M
Capital Lease Obligations	0	0	0	0	40.94M	71.03M	71.73M	64.8M	54.81M	44.65M
Deferred Tax Liabilities	-105.93M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.47M	11.43M	16.5M	16.87M	21.46M	17.44M	67.44M	37.79M	38.27M	37.06M
Total Liabilities	171.23M	172.49M	348.89M	368.13M	476.12M	654.83M	1.34B	906.19M	704.26M	775.17M
Total Debt+	105.93M	108.74M	276.5M	290.93M	351.92M	541.13M	1.13B	763.39M	586.04M	638.85M
Net Debt	-53.04M	72.79M	222.37M	158.4M	273.69M	441.17M	543.27M	659.25M	432.75M	362.08M
Debt / Equity	0.49x	0.50x	0.99x	0.91x	0.99x	0.87x	1.55x	0.99x	0.67x	0.82x
Debt / EBITDA	5.06x	-	-	10.00x	11.71x	8.17x	9.53x	5.04x	3.59x	118.00x
Net Debt / EBITDA	-2.53x	-	-	5.45x	9.11x	6.66x	4.59x	4.35x	2.65x	66.88x
Interest Coverage	1.22x	-4.54x	-1.38x	0.73x	0.44x	1.81x	3.10x	1.69x	5.06x	-4.43x
Total Equity+	218.39M	218.98M	279.48M	321.23M	354.94M	619.69M	730.41M	775.01M	870.13M	778.35M
Equity Growth %	0.28%	0%	0.28%	0.15%	0.1%	0.75%	0.18%	0.06%	0.12%	-0.11%
Book Value per Share	5.29	5.88	7.02	7.85	8.55	14.19	16.01	16.65	16.74	16.83
Total Shareholders' Equity	218.39M	218.98M	279.48M	321.23M	354.94M	619.69M	730.41M	775.01M	870.13M	778.35M
Common Stock	37K	37K	41K	41K	42K	44K	45K	46K	46K	47K
Retained Earnings	-308.29M	-346.24M	-389.14M	-388.23M	-399.4M	-253.88M	-211.9M	-148.75M	-106.8M	-206.36M
Treasury Stock	0	0	0	0	0	0	0	0	0	-25.12M
Accumulated OCI	-52K	-30K	-454K	-280K	322K	318K	167K	-380K	247K	343K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	29M	33.45M	17.79M	48.87M	70.52M	77.03M	125.72M	145.27M	154.65M	189.39M
Operating CF Margin %	0.12%	0.12%	0.06%	0.14%	0.17%	0.18%	0.23%	0.22%	0.23%	0.27%
Operating CF Growth %	0.14%	0.15%	-0.47%	1.75%	0.44%	0.09%	0.63%	0.16%	0.06%	0.22%
Net Income	1.86M	-37.95M	-42.61M	-471K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M
Depreciation & Amortization	11.47M	12.92M	13.83M	13.16M	19.58M	19.91M	28.55M	91.5M	75.57M	78.78M
Stock-Based Compensation	33.37M	31.25M	31.6M	31.73M	33.65M	39.92M	42.25M	0	47.9M	51.17M
Deferred Taxes	58K	389K	5.87M	919K	-1.83M	-126.61M	10.87M	-7.95M	15.62M	20.62M
Other Non-Cash Items	4.58M	4.57M	11.67M	14.39M	37.08M	22.68M	20.75M	62.24M	19.39M	156.89M
Working Capital Changes	-22.34M	22.28M	-2.57M	-10.86M	-6.94M	-24.39M	-18.67M	-16.43M	-45.78M	-18.52M
Change in Receivables	-3.49M	-4.08M	-1.72M	-6M	-8.52M	-5.52M	-10.43M	-2.08M	-7.16M	-7.75M
Change in Inventory	-32.38M	30.37M	-10.13M	-7.16M	-8.03M	-6.35M	-4.47M	2.49M	-8.29M	-20.93M
Change in Payables	9.94M	-2.58M	12.84M	-573K	-1.82M	-3.31M	-10.26M	6.27M	916K	3.08M
Cash from Investing+	-20.23M	-61.75M	-223.76M	20.58M	-128.49M	-277.61M	-20.79M	-225.19M	77.54M	-83.28M
Capital Expenditures	-41.27M	-24.71M	-19.27M	-14.51M	-10.16M	-37.8M	-45.87M	-30.08M	-15.16M	-10.64M
CapEx % of Revenue	0.17%	0.09%	0.07%	0.04%	0.02%	0.09%	0.08%	0.05%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-119K	143K	-8.46M	157K	0	0	-4M	-32M	0	0
Cash from Financing+	10.7M	7.26M	224.16M	8.95M	3.67M	222.3M	380.69M	-401.53M	-183.03M	17.36M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	12.17M	7.26M	-2.65M	8.95M	4.01M	29.69M	16.94M	-1.18M	-2.16M	-34.25M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.27M	8.74M	-1.48M	34.36M	60.36M	39.23M	79.85M	115.2M	139.49M	178.75M
FCF Margin %	-0.05%	0.03%	-0.01%	0.1%	0.14%	0.09%	0.15%	0.17%	0.21%	0.26%
FCF Growth %	-4.43%	1.71%	-1.17%	24.2%	0.76%	-0.35%	1.04%	0.44%	0.21%	0.28%
FCF per Share	-0.30	0.23	-0.04	0.84	1.45	0.90	1.75	2.48	2.68	3.87
FCF Conversion (FCF/Net Income)	15.62x	-0.88x	-0.42x	-103.76x	-6.40x	0.53x	2.99x	9.13x	3.69x	-1.90x
Interest Paid	4.22M	3.85M	6.9M	8.21M	8.2M	7.21M	7M	0	27.64M	15.42M
Taxes Paid	195K	247K	129K	128K	863K	2.42M	3.22M	0	4.37M	11.02M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	0.95%	-17.35%	-17.1%	-0.16%	-3.26%	29.86%	6.22%	2.11%	5.1%	-12.08%
Return on Invested Capital (ROIC)	5.04%	-10.51%	-4.71%	2.43%	1.42%	4.12%	5.78%	3.32%	4.8%	-4.5%
Gross Margin	71.15%	60.16%	69.33%	74.25%	74.65%	72.69%	74.1%	70.11%	72.64%	75.69%
Net Margin	0.75%	-13.73%	-14.87%	-0.14%	-2.62%	33.87%	7.75%	2.39%	6.22%	-14.2%
Debt / Equity	0.49x	0.50x	0.99x	0.91x	0.99x	0.87x	1.55x	0.99x	0.67x	0.82x
Interest Coverage	1.22x	-4.54x	-1.38x	0.73x	0.44x	1.81x	3.10x	1.69x	5.06x	-4.43x
FCF Conversion	15.62x	-0.88x	-0.42x	-103.76x	-6.40x	0.53x	2.99x	9.13x	3.69x	-1.90x
Revenue Growth	25.97%	10.99%	3.71%	17.67%	24.83%	2.05%	26.04%	23.14%	1.22%	3.85%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	-	426.61M	-	664.15M	672.25M	697.19M
Product Growth	-	-	-	-	-	1.22%	3.71%
EXPAREL	331.11M	-	-	506.51M	536.9M	538.12M	548.96M
EXPAREL Growth	-	-	-	-	6.00%	0.23%	2.01%
ZILRETTA	-	-	-	12.68M	105.52M	111.1M	118.09M
ZILRETTA Growth	-	-	-	-	731.96%	5.29%	6.29%
Bupivacaine Liposome Injectable Suspension	-	-	-	3.61M	6.48M	3.34M	7.32M
Bupivacaine Liposome Injectable Suspension Growth	-	-	-	-	79.59%	-48.39%	119.09%
Royalty	-	-	3.03M	-	-	-	-
Royalty Growth	-	-	-	-	-	-	-
EXPAREL/bupivacaine liposome injectable suspension	-	411.03M	-	-	-	-	-
EXPAREL/bupivacaine liposome injectable suspension Growth	-	-	-	-	-	-	-
DepoCyte	-	-	-	-	-	-	-
DepoCyte Growth	-	-	-	-	-	-	-
DepoCyt(e) and Other Products	1.31M	-	-	-	-	-	-
DepoCyt(e) and Other Products Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Pacira BioSciences, Inc. (PCRX) reported $716.8M in revenue for fiscal year 2024. This represents a 4469% increase from $15.7M in 2011.

Pacira BioSciences, Inc. (PCRX) grew revenue by 3.9% over the past year. Growth has been modest.

Yes, Pacira BioSciences, Inc. (PCRX) is profitable, generating $21.4M in net income for fiscal year 2024 (-14.2% net margin).

Dividend & Returns

Pacira BioSciences, Inc. (PCRX) has a return on equity (ROE) of -12.1%. Negative ROE indicates the company is unprofitable.

Pacira BioSciences, Inc. (PCRX) generated $124.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Pacira BioSciences, Inc. (PCRX) 10-Year Financial Performance & Capital Metrics

PCRX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

Revenue $701M +3.9%
EBITDA $5M -96.7%
Net Income -$100M -337.3%
EPS (Diluted) -2.15 -341.6%
Gross Margin 75.69% +4.2%
EBITDA Margin 0.77% -96.8%
Operating Margin -10.47% -180.6%
Net Margin -14.2% -328.5%
ROE -12.08% -336.8%
ROIC -4.5% -193.7%
Debt/Equity 0.82 +21.9%
Interest Coverage -4.43 -187.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 25.5% free cash flow margin
✓Strong 5Y sales CAGR of 10.7%
✓Share count reduced 11.0% through buybacks
✓Trading at only 1.2x book value

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.49%

5Y10.73%

3Y8.98%

TTM3.14%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM123.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM121.93%

ROCE

10Y Avg0.89%

5Y Avg3.32%

3Y Avg1.44%

Latest-5.39%

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	249M	276.37M	286.63M	337.28M	421.03M	429.65M	541.53M	666.82M	674.98M	700.97M
Revenue Growth %	0.26%	0.11%	0.04%	0.18%	0.25%	0.02%	0.26%	0.23%	0.01%	0.04%
Cost of Goods Sold+	71.84M	110.1M	87.92M	86.84M	106.71M	117.33M	140.25M	199.29M	184.67M	170.43M
COGS % of Revenue	0.29%	0.4%	0.31%	0.26%	0.25%	0.27%	0.26%	0.3%	0.27%	0.24%
Gross Profit+	177.16M	166.27M	198.72M	250.43M	314.31M	312.32M	401.28M	467.53M	490.31M	530.54M
Gross Margin %	0.71%	0.6%	0.69%	0.74%	0.75%	0.73%	0.74%	0.7%	0.73%	0.76%
Gross Profit Growth %	0.47%	-0.06%	0.2%	0.26%	0.26%	-0.01%	0.28%	0.17%	0.05%	0.08%
Operating Expenses+	167.71M	198.29M	218.78M	232.95M	303.83M	265.97M	311.35M	407.5M	402.63M	603.91M
OpEx % of Revenue	0.67%	0.72%	0.76%	0.69%	0.72%	0.62%	0.57%	0.61%	0.6%	0.86%
Selling, General & Admin	139.04M	152.61M	161.49M	177.26M	200.78M	193.52M	199.34M	254.52M	269.44M	294.1M
SG&A % of Revenue	0.56%	0.55%	0.56%	0.53%	0.48%	0.45%	0.37%	0.38%	0.4%	0.42%
Research & Development	28.66M	45.68M	57.29M	55.69M	72.12M	59.42M	55.55M	84.8M	76.26M	81.58M
R&D % of Revenue	0.12%	0.17%	0.2%	0.17%	0.17%	0.14%	0.1%	0.13%	0.11%	0.12%
Other Operating Expenses	-165K	-82K	167K	-888K	30.93M	13.03M	56.46M	68.19M	56.94M	228.23M
Operating Income+	9.46M	-32.02M	-24.94M	15.91M	10.48M	46.35M	89.92M	60.02M	87.67M	-73.37M
Operating Margin %	0.04%	-0.12%	-0.09%	0.05%	0.02%	0.11%	0.17%	0.09%	0.13%	-0.1%
Operating Income Growth %	2.83%	-4.39%	0.22%	1.64%	-0.34%	3.42%	0.94%	-0.33%	0.46%	-1.84%
EBITDA+	20.93M	-19.11M	-11.1M	29.08M	30.06M	66.26M	118.47M	151.53M	163.25M	5.41M
EBITDA Margin %	0.08%	-0.07%	-0.04%	0.09%	0.07%	0.15%	0.22%	0.23%	0.24%	0.01%
EBITDA Growth %	3.3%	-1.91%	0.42%	3.62%	0.03%	1.2%	0.79%	0.28%	0.08%	-0.97%
D&A (Non-Cash Add-back)	11.47M	12.92M	13.83M	13.16M	19.58M	19.91M	28.55M	91.5M	75.57M	78.78M
EBIT	9.46M	-31.39M	-25.8M	19.89M	11.17M	43.6M	85.4M	48.88M	79.01M	-49.67M
Net Interest Income+	-7.05M	-5.74M	-13.97M	-15.45M	-16.25M	-21.04M	-28.1M	-31.03M	-5.87M	3.12M
Interest Income	678K	1.32M	4.08M	6.5M	7.38M	4.63M	896K	4.54M	11.44M	19.69M
Interest Expense	7.72M	7.06M	18.05M	21.95M	23.63M	25.67M	29M	35.58M	17.31M	16.57M
Other Income/Expense	-7.33M	-5.82M	-17.53M	-16.34M	-21.23M	-26.26M	-33.52M	-46.72M	-25.97M	10.27M
Pretax Income+	2.12M	-37.84M	-42.47M	-425K	-10.75M	20.09M	56.4M	13.3M	61.7M	-63.11M
Pretax Margin %	0.01%	-0.14%	-0.15%	-0%	-0.03%	0.05%	0.1%	0.02%	0.09%	-0.09%
Income Tax+	264K	105K	140K	46K	268K	-125.43M	14.42M	-2.61M	19.75M	36.45M
Effective Tax Rate %	0.88%	1%	1%	1.11%	1.02%	7.24%	0.74%	1.2%	0.68%	1.58%
Net Income+	1.86M	-37.95M	-42.61M	-471K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M
Net Margin %	0.01%	-0.14%	-0.15%	-0%	-0.03%	0.34%	0.08%	0.02%	0.06%	-0.14%
Net Income Growth %	1.14%	-21.45%	-0.12%	0.99%	-22.39%	14.21%	-0.71%	-0.62%	1.64%	-3.37%
Net Income (Continuing)	1.86M	-37.95M	-42.61M	-471K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.04	-1.02	-1.07	-0.01	-0.27	3.33	0.92	0.34	0.89	-2.15
EPS Growth %	1.1%	-26.5%	-0.05%	0.99%	-22.48%	13.33%	-0.72%	-0.63%	1.62%	-3.42%
EPS (Basic)	0.05	-1.02	-1.07	-0.01	-0.27	3.41	0.95	0.35	0.91	-2.15
Diluted Shares Outstanding	41.3M	37.24M	39.81M	40.91M	41.51M	43.68M	45.63M	46.54M	51.98M	46.24M
Basic Shares Outstanding	36.54M	37.2M	39.81M	40.91M	41.51M	42.67M	44.26M	45.52M	46.22M	46.24M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	252.58M	243.09M	391.11M	477.97M	408.56M	651.62M	866.05M	498.33M	509.99M	745.13M
Cash & Short-Term Investments	158.97M	172.6M	311.35M	383.45M	291.95M	521.66M	656.41M	288.65M	278.58M	484.62M
Cash Only	158.97M	35.94M	54.13M	132.53M	78.23M	99.96M	585.58M	104.14M	153.3M	276.77M
Short-Term Investments	0	136.65M	257.22M	250.93M	213.72M	421.7M	70.83M	184.51M	125.28M	207.84M
Accounts Receivable	25.86M	29.94M	31.66M	38M	47.53M	53.05M	96.32M	98.4M	105.56M	113.3M
Days Sales Outstanding	37.9	39.54	40.31	41.12	41.21	45.06	64.92	53.86	57.08	59
Inventory	61.65M	31.28M	41.41M	48.57M	58.3M	64.65M	98.55M	96.06M	104.35M	125.28M
Days Inventory Outstanding	313.21	103.69	171.93	204.13	199.4	201.12	256.47	175.94	206.25	268.31
Other Current Assets	6.12M	9.28M	6.69M	7.95M	0	0	0	15.22M	21.5M	21.93M
Total Non-Current Assets+	137.04M	148.38M	237.26M	211.38M	422.51M	622.89M	1.21B	1.18B	1.06B	808.39M
Property, Plant & Equipment	90.32M	101.02M	107.05M	108.67M	142.81M	211.18M	264.81M	254.39M	234.95M	216.39M
Fixed Asset Turnover	2.76x	2.74x	2.68x	3.10x	2.95x	2.03x	2.04x	2.62x	2.87x	3.24x
Goodwill	30.88M	46.74M	55.2M	62.04M	99.55M	99.55M	145.18M	163.24M	163.24M	0
Intangible Assets	81K	0	0	0	104.39M	96.52M	623.97M	540.55M	483.26M	425.97M
Long-Term Investments	13.46M	0	74.19M	40.02M	64.8M	95.46M	0	37.21M	2.41M	29.45M
Other Non-Current Assets	2.29M	624K	825K	657K	10.97M	14.02M	21.99M	27.17M	36.05M	6.2M
Total Assets+	389.62M	391.47M	628.37M	689.35M	831.07M	1.27B	2.08B	1.68B	1.57B	1.55B
Asset Turnover	0.64x	0.71x	0.46x	0.49x	0.51x	0.34x	0.26x	0.40x	0.43x	0.45x
Asset Growth %	0.19%	0%	0.61%	0.1%	0.21%	0.53%	0.63%	-0.19%	-0.06%	-0.01%
Total Current Liabilities+	151.68M	44.84M	56.22M	60.66M	107.67M	253.33M	521.12M	147.77M	97.38M	309.92M
Accounts Payable	8.74M	7.51M	14.66M	14.37M	12.8M	10.43M	10.54M	15.22M	15.7M	19.13M
Days Payables Outstanding	44.4	24.9	60.86	60.39	43.78	32.45	27.44	27.87	31.03	40.98
Short-Term Debt	104.04M	0	324K	338K	0	149.65M	374.7M	33.65M	8.64M	201.78M
Deferred Revenue (Current)	1000K	595K	102K	0	0	0	0	0	0	0
Other Current Liabilities	23.43M	25.44M	28.76M	1.62M	40.44M	36.94M	45.49M	26.2M	42.56M	28.81M
Current Ratio	1.67x	5.42x	6.96x	7.88x	3.79x	2.57x	1.66x	3.37x	5.24x	2.40x
Quick Ratio	1.26x	4.72x	6.22x	7.08x	3.25x	2.32x	1.47x	2.72x	4.17x	2.00x
Cash Conversion Cycle	306.71	118.33	151.39	184.87	196.82	213.74	293.95	201.92	232.31	286.33
Total Non-Current Liabilities+	19.55M	127.65M	292.67M	307.47M	368.45M	401.5M	823.83M	758.42M	606.87M	465.25M
Long-Term Debt	0	108.74M	276.17M	290.59M	306.05M	313.03M	674.53M	655.82M	513.8M	383.55M
Capital Lease Obligations	0	0	0	0	40.94M	71.03M	71.73M	64.8M	54.81M	44.65M
Deferred Tax Liabilities	-105.93M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.47M	11.43M	16.5M	16.87M	21.46M	17.44M	67.44M	37.79M	38.27M	37.06M
Total Liabilities	171.23M	172.49M	348.89M	368.13M	476.12M	654.83M	1.34B	906.19M	704.26M	775.17M
Total Debt+	105.93M	108.74M	276.5M	290.93M	351.92M	541.13M	1.13B	763.39M	586.04M	638.85M
Net Debt	-53.04M	72.79M	222.37M	158.4M	273.69M	441.17M	543.27M	659.25M	432.75M	362.08M
Debt / Equity	0.49x	0.50x	0.99x	0.91x	0.99x	0.87x	1.55x	0.99x	0.67x	0.82x
Debt / EBITDA	5.06x	-	-	10.00x	11.71x	8.17x	9.53x	5.04x	3.59x	118.00x
Net Debt / EBITDA	-2.53x	-	-	5.45x	9.11x	6.66x	4.59x	4.35x	2.65x	66.88x
Interest Coverage	1.22x	-4.54x	-1.38x	0.73x	0.44x	1.81x	3.10x	1.69x	5.06x	-4.43x
Total Equity+	218.39M	218.98M	279.48M	321.23M	354.94M	619.69M	730.41M	775.01M	870.13M	778.35M
Equity Growth %	0.28%	0%	0.28%	0.15%	0.1%	0.75%	0.18%	0.06%	0.12%	-0.11%
Book Value per Share	5.29	5.88	7.02	7.85	8.55	14.19	16.01	16.65	16.74	16.83
Total Shareholders' Equity	218.39M	218.98M	279.48M	321.23M	354.94M	619.69M	730.41M	775.01M	870.13M	778.35M
Common Stock	37K	37K	41K	41K	42K	44K	45K	46K	46K	47K
Retained Earnings	-308.29M	-346.24M	-389.14M	-388.23M	-399.4M	-253.88M	-211.9M	-148.75M	-106.8M	-206.36M
Treasury Stock	0	0	0	0	0	0	0	0	0	-25.12M
Accumulated OCI	-52K	-30K	-454K	-280K	322K	318K	167K	-380K	247K	343K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	29M	33.45M	17.79M	48.87M	70.52M	77.03M	125.72M	145.27M	154.65M	189.39M
Operating CF Margin %	0.12%	0.12%	0.06%	0.14%	0.17%	0.18%	0.23%	0.22%	0.23%	0.27%
Operating CF Growth %	0.14%	0.15%	-0.47%	1.75%	0.44%	0.09%	0.63%	0.16%	0.06%	0.22%
Net Income	1.86M	-37.95M	-42.61M	-471K	-11.02M	145.52M	41.98M	15.91M	41.95M	-99.56M
Depreciation & Amortization	11.47M	12.92M	13.83M	13.16M	19.58M	19.91M	28.55M	91.5M	75.57M	78.78M
Stock-Based Compensation	33.37M	31.25M	31.6M	31.73M	33.65M	39.92M	42.25M	0	47.9M	51.17M
Deferred Taxes	58K	389K	5.87M	919K	-1.83M	-126.61M	10.87M	-7.95M	15.62M	20.62M
Other Non-Cash Items	4.58M	4.57M	11.67M	14.39M	37.08M	22.68M	20.75M	62.24M	19.39M	156.89M
Working Capital Changes	-22.34M	22.28M	-2.57M	-10.86M	-6.94M	-24.39M	-18.67M	-16.43M	-45.78M	-18.52M
Change in Receivables	-3.49M	-4.08M	-1.72M	-6M	-8.52M	-5.52M	-10.43M	-2.08M	-7.16M	-7.75M
Change in Inventory	-32.38M	30.37M	-10.13M	-7.16M	-8.03M	-6.35M	-4.47M	2.49M	-8.29M	-20.93M
Change in Payables	9.94M	-2.58M	12.84M	-573K	-1.82M	-3.31M	-10.26M	6.27M	916K	3.08M
Cash from Investing+	-20.23M	-61.75M	-223.76M	20.58M	-128.49M	-277.61M	-20.79M	-225.19M	77.54M	-83.28M
Capital Expenditures	-41.27M	-24.71M	-19.27M	-14.51M	-10.16M	-37.8M	-45.87M	-30.08M	-15.16M	-10.64M
CapEx % of Revenue	0.17%	0.09%	0.07%	0.04%	0.02%	0.09%	0.08%	0.05%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-119K	143K	-8.46M	157K	0	0	-4M	-32M	0	0
Cash from Financing+	10.7M	7.26M	224.16M	8.95M	3.67M	222.3M	380.69M	-401.53M	-183.03M	17.36M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	12.17M	7.26M	-2.65M	8.95M	4.01M	29.69M	16.94M	-1.18M	-2.16M	-34.25M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.27M	8.74M	-1.48M	34.36M	60.36M	39.23M	79.85M	115.2M	139.49M	178.75M
FCF Margin %	-0.05%	0.03%	-0.01%	0.1%	0.14%	0.09%	0.15%	0.17%	0.21%	0.26%
FCF Growth %	-4.43%	1.71%	-1.17%	24.2%	0.76%	-0.35%	1.04%	0.44%	0.21%	0.28%
FCF per Share	-0.30	0.23	-0.04	0.84	1.45	0.90	1.75	2.48	2.68	3.87
FCF Conversion (FCF/Net Income)	15.62x	-0.88x	-0.42x	-103.76x	-6.40x	0.53x	2.99x	9.13x	3.69x	-1.90x
Interest Paid	4.22M	3.85M	6.9M	8.21M	8.2M	7.21M	7M	0	27.64M	15.42M
Taxes Paid	195K	247K	129K	128K	863K	2.42M	3.22M	0	4.37M	11.02M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	0.95%	-17.35%	-17.1%	-0.16%	-3.26%	29.86%	6.22%	2.11%	5.1%	-12.08%
Return on Invested Capital (ROIC)	5.04%	-10.51%	-4.71%	2.43%	1.42%	4.12%	5.78%	3.32%	4.8%	-4.5%
Gross Margin	71.15%	60.16%	69.33%	74.25%	74.65%	72.69%	74.1%	70.11%	72.64%	75.69%
Net Margin	0.75%	-13.73%	-14.87%	-0.14%	-2.62%	33.87%	7.75%	2.39%	6.22%	-14.2%
Debt / Equity	0.49x	0.50x	0.99x	0.91x	0.99x	0.87x	1.55x	0.99x	0.67x	0.82x
Interest Coverage	1.22x	-4.54x	-1.38x	0.73x	0.44x	1.81x	3.10x	1.69x	5.06x	-4.43x
FCF Conversion	15.62x	-0.88x	-0.42x	-103.76x	-6.40x	0.53x	2.99x	9.13x	3.69x	-1.90x
Revenue Growth	25.97%	10.99%	3.71%	17.67%	24.83%	2.05%	26.04%	23.14%	1.22%	3.85%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	-	426.61M	-	664.15M	672.25M	697.19M
Product Growth	-	-	-	-	-	1.22%	3.71%
EXPAREL	331.11M	-	-	506.51M	536.9M	538.12M	548.96M
EXPAREL Growth	-	-	-	-	6.00%	0.23%	2.01%
ZILRETTA	-	-	-	12.68M	105.52M	111.1M	118.09M
ZILRETTA Growth	-	-	-	-	731.96%	5.29%	6.29%
Bupivacaine Liposome Injectable Suspension	-	-	-	3.61M	6.48M	3.34M	7.32M
Bupivacaine Liposome Injectable Suspension Growth	-	-	-	-	79.59%	-48.39%	119.09%
Royalty	-	-	3.03M	-	-	-	-
Royalty Growth	-	-	-	-	-	-	-
EXPAREL/bupivacaine liposome injectable suspension	-	411.03M	-	-	-	-	-
EXPAREL/bupivacaine liposome injectable suspension Growth	-	-	-	-	-	-	-
DepoCyte	-	-	-	-	-	-	-
DepoCyte Growth	-	-	-	-	-	-	-
DepoCyt(e) and Other Products	1.31M	-	-	-	-	-	-
DepoCyt(e) and Other Products Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Pacira BioSciences, Inc. (PCRX) reported $716.8M in revenue for fiscal year 2024. This represents a 4469% increase from $15.7M in 2011.

Pacira BioSciences, Inc. (PCRX) grew revenue by 3.9% over the past year. Growth has been modest.

Yes, Pacira BioSciences, Inc. (PCRX) is profitable, generating $21.4M in net income for fiscal year 2024 (-14.2% net margin).

Dividend & Returns

Pacira BioSciences, Inc. (PCRX) has a return on equity (ROE) of -12.1%. Negative ROE indicates the company is unprofitable.

Pacira BioSciences, Inc. (PCRX) generated $124.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.